DnB Asset Management AS Boosts Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

DnB Asset Management AS boosted its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 589.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,215 shares of the company’s stock after purchasing an additional 25,834 shares during the quarter. DnB Asset Management AS owned approximately 0.09% of TransMedics Group worth $1,884,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. The Manufacturers Life Insurance Company raised its stake in shares of TransMedics Group by 3.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 18,473 shares of the company’s stock worth $2,900,000 after acquiring an additional 657 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of TransMedics Group during the 3rd quarter valued at $1,604,000. Captrust Financial Advisors lifted its holdings in shares of TransMedics Group by 20.6% during the 3rd quarter. Captrust Financial Advisors now owns 1,988 shares of the company’s stock valued at $312,000 after purchasing an additional 340 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of TransMedics Group in the 3rd quarter worth $334,000. Finally, ClearAlpha Technologies LP purchased a new position in TransMedics Group during the 3rd quarter worth $247,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on TMDX. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Robert W. Baird dropped their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a report on Tuesday, December 3rd. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, TransMedics Group presently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Price Performance

Shares of TMDX opened at $68.27 on Wednesday. The business’s 50-day moving average is $69.54 and its two-hundred day moving average is $86.52. The company has a market capitalization of $2.30 billion, a P/E ratio of 72.63 and a beta of 2.12. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.